Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Fluocinonide (Primary) ; Imiquimod (Primary)
- Indications Mycosis fungoides
- Focus Therapeutic Use
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 12 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Aug 2019.
- 12 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2019.